Abstract

Discovery and Development of Monoclonal Antibodies Targeting Tumor Neo-Epitopes

Philip Arlen, President and CEO, Precision Biologics, Inc

An allogeneic cancer vaccine developed from human tumors surgically resected had demonstrated anti-tumor responses in a clinical trial. These responses correlated with the ability of patients to mount and sustain antibody responses against the vaccine. This vaccine was utilized as a platform to identify monoclonal antibodies with tumor sensitivity, specificity and anti-tumor killing.